- Home
- MLTX
as 12-18-2024 9:40am EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $77.43 | AVG Volume (30 days): | 170.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.55 - $64.98 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MoonLake Immunotherapeutics (MLTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | MLTX | Director10% Owner | Oct 4 '24 | Sell | $50.00 | 2,000,000 | $100,003,200.00 | 10,235,089 | |
| Sturge Simon | MLTX | Director | Oct 4 '24 | Sell | $53.72 | 171,000 | $9,186,120.00 | 171,980 |
Latest MoonLake Immunotherapeutics News
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MT Newswires
a month ago
MoonLake Immunotherapeutics' Q3 Net Loss Widens
GlobeNewswire
a month ago
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 10/09/2024
GuruFocus.com
2 months ago
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics
MT Newswires
2 months ago
Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing
Insider Monkey
3 months ago
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
Insider Monkey
3 months ago
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
Compare MLTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.